ETICOVO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ETICOVO (ETICOVO).
Eticovo (etanercept) is a tumor necrosis factor (TNF) blocker. It is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kDa (p75) TNF receptor linked to the Fc portion of human IgG1. Etanercept binds specifically to TNF and blocks its interaction with cell surface TNF receptors, thereby inhibiting TNF-mediated proinflammatory cytokine and chemokine release.
| Metabolism | Etanercept is a large protein molecule that is expected to be degraded via proteolysis into peptides and amino acids. No specific metabolic pathways or enzymes have been identified. |
| Excretion | Primarily renal excretion as unchanged drug (approximately 70-80%) with about 10-20% biliary/fecal elimination. No active metabolites identified. |
| Half-life | Terminal elimination half-life is approximately 12-15 hours in patients with normal renal function, allowing twice-daily dosing. In renal impairment (CrCl < 30 mL/min), half-life may extend to >30 hours. |
| Protein binding | Approximately 90% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Apparent volume of distribution is approximately 10-15 L/kg, indicating extensive tissue penetration (e.g., liver, kidneys, lungs). |
| Bioavailability | Oral bioavailability is approximately 80-95% (co-administered with food may slightly increase absorption). |
| Onset of Action | For oral administration, peak plasma concentrations achieved in 1-2 hours; clinical effect (e.g., antiviral activity) observed within 24 hours of first dose. |
| Duration of Action | Clinical effect persists for the dosing interval of 12 hours. Steady-state achieved within 3-5 days. Duration may be prolonged in renal impairment. |
Intravenous infusion of 400 mg once daily for 4 weeks, followed by 400 mg every 4 weeks for 4 additional doses.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (eGFR ≥30 mL/min/1.73 m²). Not recommended for severe renal impairment (eGFR <30 mL/min/1.73 m²) or ESRD. |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not recommended for moderate to severe hepatic impairment (Child-Pugh B or C). |
| Pediatric use | Not approved for pediatric use; safety and efficacy not established in patients <18 years. |
| Geriatric use | No specific dose adjustment recommended; clinical studies included patients ≥65 years with no overall differences in safety or efficacy observed. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ETICOVO (ETICOVO).
| Breastfeeding | No data on presence in human milk or effects on breastfed infant. M/P ratio unknown. Due to potential for serious adverse reactions, breastfeeding is not recommended during treatment and for at least 1 week after last dose. |
| Teratogenic Risk | ETICOVO (etrasimod) is Pregnancy Category X based on animal studies showing teratogenicity including cardiovascular malformations and skeletal anomalies at clinically relevant doses. There are no adequate human studies. Use is contraindicated in pregnancy. Risk in first trimester: high risk of major congenital malformations. Second and third trimesters: fetal growth restriction and potential for preterm birth. |
■ FDA Black Box Warning
Patients treated with etanercept are at increased risk for serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Etanercept should be discontinued if a patient develops a serious infection or sepsis. Reported infections include invasive fungal infections (e.g., histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis), bacterial infections (e.g., legionella, listeria), and viral infections (e.g., tuberculosis).
| Serious Effects |
["Known hypersensitivity to etanercept or any of its components","Sepsis","Active infection (including chronic or localized infection)"]
| Precautions | ["Serious infections (including tuberculosis, invasive fungal infections, and other opportunistic infections)","Malignancies (including lymphoma, leukemia, and other malignancies)","Hepatitis B virus reactivation","Allergic reactions (including anaphylaxis and angioedema)","Neurologic events (including new onset or exacerbation of demyelinating disorders, such as multiple sclerosis and Guillain-Barré syndrome)","Hematologic reactions (including pancytopenia and aplastic anemia)","Congestive heart failure (new onset or worsening)","Autoimmunity (including development of lupus-like syndrome)","Vaccinations (live vaccines should not be given concurrently)","Immunosuppression"] |
Loading safety data…
| Fetal Monitoring | Effective contraception required before, during, and for 1 week after treatment. For inadvertent pregnancy exposure, immediate discontinuation and referral to maternal-fetal medicine for fetal ultrasound to assess for anomalies. |
| Fertility Effects | Animal studies show impaired fertility in females (prolonged estrous cycles, reduced implantation) at exposures similar to human therapeutic doses. No male fertility data. Clinical significance unknown. |